GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Scancell Holdings SCLP.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

79.00p

-1.25%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Scancell Holdings — daily SCLP

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Scancell Holdings on TradingView ↗
Market value
£766.6m
Last close × shares
Volume
73.9k
Shares, 20 Nov 2026

About Scancell Holdings

Its shares trade on LSE under the ticker SCLP.L. It has been listed since 30 July 2010. In the fiscal year to 30 April 2025, it reported revenue of £4.7m and a net loss of £12.3m. At that date it held total assets of £23.1m and shareholders' equity of −£3.8m.

Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2010-07-30. The firm's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The firm is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The firm's products include SCIB1, SCIB2 and Modi-1. The firm's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. The company is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The firm's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Figures and description from our data supplier, not checked against the company's own report.

More about Scancell Holdings →

Latest on Scancell Holdings

Our reporting

Next results

4 Feb 2027

Due on 4 Feb 2027. Analysts expect earnings of -0.09 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Scancell Holdings's ticker?

Scancell Holdings trades as SCLP.L on LSE, under ISIN GB00B63D3314.

What was Scancell Holdings's last closing price?

79.00p on 20 Nov 2026. The figure is in GBp and is never converted.

When does Scancell Holdings next report results?

Results are expected on 4 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.